EDF Health

FDA’s squishy definition of adverse health effects of substances in food

Maricel Maffini, consultant, and Tom Neltner, Senior Director, Safer Chemicals

3 human figures showing stages of becoming ill. First figure is all white and standing up straight. Second figure is bent over and stomach area is red. Third figure is is all red, bent over, and appears to be vomiting.

What Happened

A recent peer-reviewed publication criticized FDA’s criteria for identifying adverse health effects associated with exposure to pathogens, chemicals, or allergens in foods. The authors gave two recent examples of the agency dismissing health concerns: a toxin created in spoiled fish that caused temporary, medically adverse health effects because they were short-term and reversible, and an additive where evidence from animal testing showed harm in only one sex. The authors concluded that the agency’s criteria are “inadequate because they are not science-based.”

Why It Matters

FDA is responsible for protecting food safety and the public’s health. In order to do that, it makes decisions whether a pathogen, chemical, or allergen causes an adverse health effect that must be avoided—so the agency’s definition of an adverse health effect is critically important. Unfortunately, FDA lacks a clear definition of the term, usually approaching it on a case-by-case basis in a manner that lacks transparency and scientific grounding.

Adverse Effects Dismissed by FDA

In 2020, the director of The Pew Charitable Trusts’ food safety project argued that FDA failed to “protect Americans from preventable illnesses” because it considered that the effects caused by the fish toxin were temporary or reversible. FDA described the toxin’s effects, which ranged from facial flushing and sweating, dizziness, nausea and headache to more severe cases of blurred vision, respiratory stress, and swelling of the tongue. The Pew director reasonably added that people may require hospitalization, medical treatment due to cardiac complications, and altered blood pressure–all of which are adverse health effects.

In a 2019 final rule approving the listing of leghemoglobin as a color additive, the Center for Food Safety objected that FDA dismissed statistically significant “changes in blood chemistry, blood clotting ability, and blood globulin values” as potential health effects. In its response to the objection, the agency argued that “statistical differences seen between control animals and treatment animals due to small changes in the value of the parameter are not likely to be of biological or toxicological significance.” FDA further stated that for the color additive to cause the blood changes to be “potentially adverse” it should:

  • Show a “clear dose-response,” described as a direct relationship between the dose given and the effect observed, in other words, the higher the dose, the higher the effect; and
  • Be observed in both sexes of the species in which the substance is tested.

This argument put forth by FDA’s food safety scientists would be summarily dismissed by their colleagues on the drug side because it ignores current scientific principles: dose responses can have different shapes and there are known sex differences in response to exposures from multiple chemicals.

Our Take

This is an ongoing issue. Other organizations have defined “adverse health effects.” For example, EPA’s Integrated Risk Information System (IRIS) defines adverse effect as “[a] biochemical change, functional impairment, or pathologic lesion that affects the performance of the whole organism, or reduces an organism’s ability to respond to an additional environmental challenge.”

FDA’s lack of a practical definition for adverse health effect and how the agency applies it in food safety assessments has likely contributed to inconsistencies in its decision making.

Next Steps

We will continue to press the agency for transparency about what health effects it considers important to prevent and protect the health of American families. FDA should publish clear, rational, science-based criteria for determining adverse effects and periodically review them as our knowledge base advances to better inform regulatory decisions.

Also posted in Adverse health effects, FDA, Health hazards, Health science, Public health, Regulation / Tagged , , , | Authors: , / Comments are closed

Representatives Call For FDA Public Hearing on Phthalates

By. Joanna Slaney, Senior Director, Federal Affairs, and Maricel Maffini, PhD, Consultant

U.S. Capitol dome framed by trees

Source: A. Paige Baker, ShutterSights.com©

What Happened?

On May 19, Reps. Katie Porter, Steve Cohen, Nanette Diaz Barragán, Earl Blumenauer, and Raúl Grijalva issued a letter [PDF, 300KB] to FDA Commissioner Robert Califf calling on FDA to “act expeditiously to protect the public from the health risks posed by phthalates in food and food packaging.”

They asked the FDA to hold a public hearing on ortho-phthalates (phthalates), chemicals associated with disruptions to the development of the male reproductive system and neurodevelopment, among other health effects.

Why It Matters

In 2021, Reps. Porter and Lieu led a letter with 12 colleagues urging FDA to take action on phthalates in food and cosmetics. That letter, in part, called on FDA to take action on a 2016 petition filed by EDF and allied environmental health organizations asking FDA to revoke its approval for all uses of phthalates in food packaging and processing equipment.

In May 2022, after the petitioners sued, FDA denied the petition. The petitioners formally objected to the decision and requested a public hearing pursuant to FDA’s regulations. The agency has not provided any timeline for acting on the objections.

Request for a Public Hearing

The Representatives stated in the letter submitted last month that  FDA’s decision denying the petition was flawed. “[W]e are deeply concerned about the denial, which was made without deciding whether the remaining approved uses of phthalates in food and food packaging are safe.” (Emphasis original)

They reminded Commissioner Califf of his recent statement that chemical safety is a “really, really important area for the future – for humankind, really – and where science is evolving rapidly,” urging FDA to hold a public hearing on two areas of concern:

  • The agency’s failure to evaluate the safety of phthalates as it was legally required to do before denying the 2016 petition. The letter stated, “failing to evaluate the safety of phthalates is an abdication of the FDA’s continuing obligation to oversee the safety of the food supply.”
  • FDA’s failure to address new toxicity information that raises significant questions about the safety of phthalates. Phthalates are associated with numerous health issues, including reproductive and developmental toxicity, endocrine disruption, immune toxicity, and epigenetic alterations. The letter stated, “the denial of the petition fails to acknowledge, let alone analyze, the dozens of peer-reviewed studies that underscore the toxicity of the phthalates that remain approved for food contact use.”

Next Steps

EDF and our allies will continue to press FDA to hold a public hearing on the safety of phthalates used in food packaging and processing equipment.

Go Deeper

EDF blogs on phthalates

Also posted in Congress, Developmental toxicity, Endocrine disruptors, FDA, Food, Food packaging, Health science, Phthalates, Public health, Public hearing, Regulation, Reproductive toxicity / Tagged , , , , , | Authors: , / Comments are closed

Unleading Baby Food: FDA’s proposed limits are a positive step, but…

Tom Neltner, Senior Director, Safer Chemicals

What Happened: FDA recently released draft action levels for lead in foods intended for babies and young toddlers.1 Action levels represent the point above which FDA is likely to regard food as adulterated – essentially unsafe – and seek a recall. This is a key step in implementing FDA’s Closer to Zero Action Plan.

  • Lead limits would be 10 parts per billion (ppb) for most foods.
  • Limits would be 20 ppb for dry infant cereals and single-ingredient root vegetable products, because these products may have greater lead contamination levels. (Root vegetables are primarily carrots and sweet potatoes.)

The new action levels do not apply to juices; FDA proposed limits on those in April 2022.

Why It Matters: There is no safe level of lead in the diet.

For young children living in homes without lead pipes or lead paint, diet is the primary source of their lead exposure. FDA makes clear in the proposal that:

“Even low lead exposure can harm children’s health and development, specifically the brain and nervous system. Neurological effects of lead exposure during early childhood include learning disabilities, behavior difficulties, and lowered IQ. Lead exposures also may be associated with immunological, cardiovascular, renal, and reproductive and/or developmental effects. Because lead can accumulate in the body, even low-level chronic exposure can be hazardous over time.”

Lead can enter the food chain through multiple sources, including crops grown in contaminated soil and/or irrigated with contaminated water, atmospheric deposition from industrial activities, and old food-processing equipment that contains lead. The objective is to get exposure closer to zero.

Our Take: We applaud FDA’s proposed limits, which are more protective than the European Union’s 2021 standards. BUT…on the flip side:

  • FDA failed to set action levels for popular grain-based snacks, like teething biscuits and snack puffs. The agency needs to rectify this failure with all deliberate speed.
  • More protective action levels are achievable, especially for non-rice cereals and for foods that don’t contain rice or root vegetables.
  • Proposed action levels do not apply to multiple categories of foods, including:
  • FDA’s justification for the draft action levels lacks transparency—undermining both credibility of the levels and the likelihood industry will comply with them.

In addition, USDA and industry need to expand their support for research on the methods for growing, harvesting, and processing root vegetables, rice, and quinoa to further reduce lead contamination in these important foods. Research should include both store-bought and homemade baby foods.

Go Deeper: Visit our new Deep Dives blog to see our 3-part series, which provides a more detailed analysis of FDA’s proposal—including our recommendations for setting more protective limits and improving the transparency and credibility of the agency’s process of setting action levels.

NOTES
1 FDA’s guidance refers to babies and young children. Younger than two is a very narrow definition of young children, especially since children up to age six are particularly vulnerable to the harm that lead causes to their brains. Other federal agencies set standards for this broader age range. Toddlers are generally considered to be between 1 and 3 years of age. Therefore, we use the term “young toddlers” to avoid confusion.

Revised on March 21 to correct quote.

Also posted in Deep Dives, FDA, Health science, Public health, Unleaded Juice / Read 1 Response

Introducing Deep Dives—EDF’s New Platform for In-Depth Scientific & Policy Analyses on Environmental Health

What’s New? Today we’re launching a new digital channel for the die-hard science and policy wonks in our midst! Deep Dives is a new, long-form blog site that will offer readers in-depth scientific analyses, hard data, and practical policy prescriptions from our top environmental health experts. The authors are Environmental Defense Fund experts in air quality, chemistry, epidemiology, law, public health, and more.Illustration of a pink brain wearing glasses on a bright yellow background

Why It Matters: We have multiple audiences for our content—and data tell us they have very different information needs and preferences about format.

We are committed to giving everyone the information they want in the format they prefer—and that led us to create Deep Dives.

Here’s the Deal: On average, only about 5% of web visitors read to the bottom of any particular piece of internet content. That’s why we have moved this blog to short-form content that tells you what’s happening and why it’s important from the jump. We give you the gist, and we try to keep it under 500 words.

But we also have a specialized audience of scientists, policymakers and implementers, academics, and advocates who value the policy nuances and scientific details. The people in this group want the meaty content and all the details—and, if they are interested in the subject, they will read to the end of the post, no matter how long it is.

If that describes you, Deep Dives was conceived and created for you!

What’s Next? We may be creating a new space for the self-described geeks and wonks, but we’ll continue to give you the skinny here—and all visitors are welcome in both spaces! Be sure to subscribe to this blog to receive email notifications of new Deep Dives blogs.

Last one in is a rotten egg!


Illustration of two French bulldogs under water, wearing swimming goggles, surrounded by a colorful coral reef.

Welcome to our new Deep Divers!

Also posted in Deep Dives, Health science, Public health / Comments are closed

Unleading Baby Food: FDA, USDA, and industry need to invest in research to reduce lead in baby food

Tom Neltner, Senior Director, Safer Chemicals Initiative

Note: This is the third of three blogs in this series. Click here for Blog 1 or Blog 2.

On January 24, 2023, FDA released draft action levels for lead in foods intended for babies and young toddlers.1 For most of these foods, the limit would be 10 parts per billion (ppb). FDA proposed a less-protective limit of 20 ppb for dry infant cereals and single-ingredient root vegetable products (i.e., carrots or sweet potatoes) because these products may have greater lead contamination levels. This proposal is a key step in implementing the agency’s Closer to Zero Action Plan.

In this blog, we take a deeper dive into the research needed for FDA to fulfill its commitment to continuously improve its action levels. We identify four issues for which FDA, USDA, and industry should support research if we are to make progress in reducing toxic element contamination of food:

Bags of riceSweet potatoes

QuinoaCarrots

Rice is highly contaminated with lead, as well as with high levels of inorganic arsenic. Rice has long-been recognized as the primary source of young children’s dietary exposure to inorganic arsenic. FDA’s data2 now make clear that lead contamination is also a significant issue. For the 299 rice cereal samples, the 90thpercentile was 21 ppb of lead, and 28% had levels of 10 ppb or more. In contrast, only 1 of 85 samples (1.2%) for non-rice or multigrain cereals had 10 ppb or more of lead, and the 90th percentile was 8 ppb, so a 10-ppb level can be met and is justified.

In 2020, FDA highlighted that inorganic arsenic concentrations for infant rice cereal had dropped from 64% greater than 100 ppb in 2011-13 to 53% in 2014 to 26% in 2018. Some of this progress can be attributed to baby food companies screening out rice with higher levels, a change that shifts the more highly contaminated products to general market. However, there is also compelling research showing that improved growing and processing methods such as intermittent flooding of fields, removing bran, and decanting cooking water significantly reduce inorganic arsenic contamination.

More research is needed to reduce lead contamination in rice and how it correlates to inorganic arsenic levels). We also need additional research on essential nutrients in rice.

Sweet potatoes commonly have significant lead contamination, but research shows promise. Lead contamination of sweet potatoes was significant enough that FDA set an action level for foods where they were the only ingredient. FDA’s three data sources evaluated 14 samples of sweet potato puree and half of the samples were above 15 ppb with the highest at 34 ppb.

Several years ago, EDF funded Dr. Arthur Villordon at Louisiana State University’s Sweet Potato Research Center to investigate the lead contamination and identify potential research opportunities. He and his team determined that much of the contamination was in the peel, suggesting that optimized peeling would be beneficial. They also identified the possible role of type of sweet potato—as well as opportunities to manage essential nutrient availability—to reduce uptake of lead.

Along with researchers from Mississippi State University, University of California—Davis, Colorado State University, and two units of USDA’s Agricultural Research Service, Dr. Villordon and his team applied to USDA last month for significant research support to evaluate those and other opportunities.

Quinoa is highly contaminated with lead and cadmium. Arsenic levels were not provided. The levels of lead in quinoa were significantly higher than rice cereal, grain snacks, or root vegetables. While the data set is older (from 2014) and much smaller (29 samples), the 90th percentile was an astounding 90 ppb of lead. In addition, 41% had 20 ppb or more of lead and 58% were over 10 ppb.3 In addition, cadmium was also present in all but two of the samples ≥ 10 ppb and 75% were ≥ 50 ppb.

EDF talked with one of the leading researchers on quinoa, Dr. Lori Hoagland of Purdue University, about opportunities to reduce contamination. She thought that changing strains of quinoa might be the best strategy, although research funds are limited.

Carrots also have significant lead contamination. As with sweet potatoes, FDA data showed that carrots were also contaminated with lead, although at lower levels than sweet potatoes—the other root vegetable common in baby food. For the 39 samples of carrot puree, the 90th percentile was 15 ppb of lead, and 20% had levels of 10 ppb or more.

Several years ago, EDF funded Dr. Hoagland to investigate lead contamination in carrots and identify potential research opportunities. She and her team determined that much of the contamination was in the outer areas of the carrots, suggesting that optimized peeling would be beneficial. They also found that a particular strain of carrot showed promise in reducing uptake of lead and cadmium.

Along with researchers from Michigan State University, Cornell University, University of Buffalo, University of California—Davis, and a unit of USDA’s Agricultural Research Service, Dr. Hoagland and her team applied to USDA last month for significant research support to determine more effective ways of reducing lead in carrots.

Additive or Synergistic Impacts of Lead, Cadmium, Arsenic, and Mercury
FDA’s Closer to Zero Action Plan focuses on four toxic elements—lead, cadmium, inorganic arsenic, and mercury. One of the early goals was to consider the cumulative effects of these toxic elements on children’s developing brains.

Dr. Piper Reid Hunt and a team at FDA’s Office of Applied Research and Safety Assessment have been studying the harm to the developing nervous systems of nematodes (C elegans) because they are similar enough to human neural development to allow helpful insights. Her important research is not yet made public.

In summary, we encourage FDA, USDA, and industry to invest in research to reduce contamination of foods with toxic elements and evaluate the research that the presence of these substances in the diet can have on children.

Sign up to receive notifications when we publish a new Deep Dives post!

1 We included all 29 samples that FDA identify as quinoa, even if the agency did not also identify it as a dry cereal.

2 1) Toxic Element Program consisting of 356 samples of dry infant cereals, fruits, mixtures and vegetables collected from 2008-2021; 2) FDA Survey 1 consisting of 147 samples of dry infant cereals and mixtures collected from 2013 to 2014; and FDA Survey 2 consisting of 360 samples of fruits, mixtures, vegetables, yogurts, custards/puddings, and single-ingredient meats collected in 2021.

3 FDA’s guidance refers to babies and young children. However, the action levels only apply to foods intended for children younger than 24 months, a very narrow definition of young children, especially since children up to six years of age are particularly vulnerable to the harm to their brain from lead. Other federal agencies set standards for this broader age range. Toddlers are generally considered to be between 1 and 3 years of age. Therefore, we use the term “toddlers” to avoid confusion.

Also posted in Deep Dives, FDA, Food, Health science, Lead / Authors: / Comments are closed

Unleading Baby Food: FDA needs to improve how it sets action levels to be more transparent and credible

Tom Neltner, Senior Director, Safer Chemicals Initiative

Note: This is the second of three blogs in this series. Click here for Blog 1 or Blog 3.

On January 24, FDA released draft action levels for lead in foods intended for babies and young toddlers.1 For most of these foods, the  limit would be 10 parts per billion (ppb). FDA proposed a less-protective limit of 20 ppb for dry infant cereals and single-ingredient root vegetable products (i.e., carrots or sweet potatoes) because these products may have greater lead contamination levels. This proposal is a key step in implementing the agency’s Closer to Zero Action Plan.

Overall, FDA fixed several problems we highlighted in our Unleaded Juice series about the agency’s draft action levels for lead in juice, which it released in April 2022. However, significant issues remain, especially regarding the agency’s transparency, that undermine the credibility—and ultimately the effectiveness—of the action levels.

We discuss the proposed action levels and recommendations for more protective limits as well as specific research needs in separate blogs. Here, we take a deeper dive into FDA’s approach to setting these action levels.

Action Levels v. Regulatory Standards
FDA’s regulation at 21 C.F.R. § 109.6 addresses unavoidable contaminants in foods. It says FDA should use action levels when “technological or other changes that might affect the appropriateness of the tolerance are foreseeable in the near future.” If the agency does not foresee changes that would reduce the contamination, the regulation indicates it should set tolerances through rulemaking. By issuing action levels, FDA is affirming its commitment to continuous improvement —a key element in its Closer to Zero Action Plan.

In general, FDA develops action levels through guidance rather than rulemaking because it claims that the process enables the agency to move more quickly and to make updates more easily. Guidance has typically been subject   to less stringent interagency review by the White House’s Office of Management and Budget (OMB).2

Nonetheless, FDA’s action levels for lead and inorganic arsenic in food have undergone OMB review, and that review has been quite lengthy.3 The delays have been significant enough that FDA revised its Closer to Zero Action Plan in January by:

  • Changing its commitment to publish draft action levels for lead and arsenic to only submitting the document for interagency review. These documents are not public until finalized.
  • Eliminating its commitments to finalize all of its draft action levels.
  • Dropping the word “Action” from the title of the program.

Lack of Transparency in Decision-Making Undermines Credibility and Effectiveness
We do not suggest that action levels need to undergo the full regulatory interagency review by OMB. However, there are elements of that review that would improve the transparency and credibility of the decision, as well as the effectiveness of the action levels. They might also accelerate OMB review. Therefore, we recommend:

Explaining the options the agency considered and why it selected the action level described in the guidance.
FDA’s current approach only compares the selected option to the status quo. We know many of the excellent FDA staff working on the issue and how seriously they approach this effort. They surely considered many variations before settling on the proposed option. However, that information is largely omitted from the proposed guidance and supporting materials. This omission makes it more difficult to provide constructive comments to the agency and undermines the credibility of the decision.

Estimating dietary exposures that protect more than just the 90th percentile of children. FDA typically uses the 90th percentile to evaluate exposure to contaminants or additives. We have not seen a rationale for selecting this value over more protective ones—like the 95th percentile commonly used in Europe for food or, in the U.S., using the 97.5th percentile to set an elevated blood lead level (CDC) or the 99th percentile for pesticides in the U.S.

As we explained in a blog on the lead-in-juice proposal, while percentiles may seem abstract, we think it is important to recognize that, in this case, they represent lead-exposed children. Using the 90th percentile means that the 2.4 million children ages 1 to 6 years who are exposed to higher levels of lead are not taken into account.4 When including children younger than age 1, the number is even greater.

Calculating the socioeconomic benefits of the options considered and the one selected. As we explained in a blog on the lead-in-juice proposal, we encourage FDA to use methods developed by EPA (and accepted by OMB) to quantify the societal benefits of reducing young children’s exposure to lead. We applied that method to estimate that a 6% reduction in exposure for children younger than six years of age would yield $1 billion per year in benefits.We think this approach is a valuable tool to help the agency and stakeholders consider options. It would also prompt industry to provide realistic estimates of the cost to achieve the limits, rather than the vague claims it often relies on.

Transparently comparing the options considered to their impact on FDA’s Interim Reference Level (IRL) of 2.2 µg/day for children. In 2018, FDA established an IRL of 3.5 µg/day. The agency describes this value as the “maximum daily intake for lead from food” of lead for children. This is not a health-based level—rather it is a target the agency uses to drive lead contamination lower through its 2021 Closer to Zero Action Plan. Using FDA’s own analysis, we estimated that more than 2 million young children (aged 1-6 years) exceeded the IRL.

In July 2022, FDA lowered the IRL to 2.2 µg/day to conform to changes in CDC’s Blood Lead Reference Level. We estimated that 7 million young children (one-third of all children in this age group) exceeded this level and called on FDA to more rigorously compare its proposal—including options considered—to the IRL. We also asked the agency to estimate the number of children who would no longer exceed the IRL as a result of each option.In the draft guidance document, FDA states that under the status quo “the 90th percentile dietary exposures for babies and young children are below the IRL for lead of 2.2 μg/day for children.” While the agency shows that 90th percentile intake of specific groupings of foods are below the IRL, the agency provides no details for how it reached that conclusion, which should apply to dietary intake from all sources and not just those covered by the action levels.5

In other words, the approach would exclude the contribution from food not covered by the action levels, such as: 1) juices; 2) grain snacks (e.g., teething biscuits, cookies, and puffs); 3) fruits, cereals, and vegetables that parents use to make homemade foods for their babies and young toddlers, even though these products are often likely to be more contaminated, regardless of whether they are organic; and 4) foods marketed for a general audience such as applesauce and canned food, that parents (especially those on tight budgets) commonly feed to children.

In addition, the Agency’s assertion contradicts that of an FDA scientist who estimated in 2019 that children 12 to 36 months had a 90th percentile lead intake of 2.6 μg/day from their diet.6 It is unclear if this is due to differences in methodology, or a true decrease in exposure between then and now.

Assuming the claim is true and that the 90th percentile is at 2.2 μg/day, it still means that 10% of the approximately four million children born each year— or about 400,000 children – exceed the IRL. This illustrates the flaw in choosing the 90th percentile to represent an “upper bound” and “a health protective measure to account for babies and young children (0-23 months) who consume larger amounts of food and would therefore have higher exposures.”

As we have previously commented, FDA’s choice of the 90th percentile is out of step with other agencies, including CDC and EPA. The agency should not only be transparent about its calculations, but it should be clear how many children will be brought below the IRL with each option considered in order to provide critical context for the strengths and weaknesses of the agency’s analysis.

Posting all toxic element testing results—not just lead—for the data supporting the guidance. When FDA evaluates a sample for lead, the lab method also provides results for cadmium, arsenic, and mercury. This is important since FDA’s Closer to Zero Action Plan is focused on the health risks to young children from lead, cadmium, mercury, and inorganic arsenic and highlights the cumulative risks from these toxic elements.

Unfortunately, FDA only provides the results for lead when it posts the supporting data for both its draft action levels for lead in juice and lead in food intended for babies and young toddlers. The agency provides no explanation for why it withholds data for the other contaminants.We raised this concern in our comments on the draft action levels for lead in juice. FDA failed to address its lack of transparency despite the opportunity and minimal burden.

Posting a red-lined version of the document that compares the original version submitted to OMB for review and the final version. Agencies, including EPA and FDA, post a comparison that shows the changes made to its rule and accompanying justification as a result of the OMB review. FDA does not do that for OMB review of guidance. The comparison helps stakeholders understand the key issues, and it poses little burden to either agency. FDA should post the red-lined version.

In summary, FDA needs improve the process by which it proposes and finalizes action levels by improving its transparency. This will make the agency’s decisions more credible—an important consideration for ensuring industry compliance with the guidance.

Up Next: Unleading Baby Food: FDA, USDA, and industry need to invest in research to reduce lead in baby food

Sign up to receive notifications when we publish a new Deep Dives post!

NOTES

1 FDA’s guidance refers to babies and young children. However, the action levels only apply to foods intended for children younger than 24 months, a very narrow definition of young children, especially since children up to six years of age are particularly vulnerable to the harm to their brain from lead. Other federal agencies set standards for this broader age range. Toddlers are generally considered to be between 1 and 3 years of age. Therefore, we use the term “toddlers” to avoid confusion.

2 Specifically, OMB’s Office of Information and Regulatory Affairs (OIRA).

3 For example: 1) Lead in food intended for babies and young toddlers where proposed guidance was under OMB review for 9 months; 2) Lead in juice where proposed guidance was under OMB review for 13 months; 3) Inorganic arsenic in infant rice cereal where final guidance was under OMB review for 4 months; and 4) Inorganic arsenic in apple juice where final guidance has been under OMB review for 21 months and counting.

4 Approximately 4 million children are born each year in the United States. Over a six-year period, that would mean ~24 million children in the age range.

5 The three values in the sixth column of Table 4 add up to 2.02 μg/day but that is not a valid method for 90th percentiles.

6 Based on the hybrid estimate from the report. Note that the lower bound is 1.8 and upper bound 4.4 μg/day.

Also posted in Deep Dives, FDA, Food, Health science, Lead / Authors: / Comments are closed